QR Kod

Extended dual antithrombotic therapy in patients with chronic coronary syndrome — which agent should be added to aspirin?

According to the 2024ESC Guidelines for the management of chronic coronary syndromes dual antithrombotic treatment comprising aspirin and a second antithrombotic drug for extended long-term prevention should be considered in patients at increased ischemic risk without high bleeding risk. However, no...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Jacek Kubica, Piotr Adamski, Katarzyna Buszko, Piotr Buszman, Nader Elmasri, Tomasz Fabiszak, Jakub Foryś, Robert Gajda, Mariusz Gąsior, Robert Gil, Paweł Grzelakowski, Tomasz Hajdukiewicz, Miłosz Jaguszewski, Adam Kern, Wacław Kochmann, Jacek Konarski, Aldona Kubica, Tobiasz Kudla, Wiktor Kuliczkowski, Aleksandra Kusińska-Czyczyło, Ewa Laskowska, Przemysław Magielski, Piotr Michalski, Krzysztof Milewski, Natalia Mrzywka, Piotr Niezgoda, Małgorzata Ostrowska, Maciej Piasecki, Przemysław Podhajski, Janusz Prokopczuk, Jakub Ratajczak, Alicja Rzepka-Cholasińska, Grzegorz Skonieczny, Giuseppe Specchia, Łukasz Szarpak, Paweł Szymański, Małgorzata Topolska, Julia M. Umińska, Marcin Ziółkowski, Aleksander Żurakowski, Eliano Pio Navarese
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Via Medica 2025-06-01
Seri Bilgileri:Cardiology Journal
Konular:
extended antithrombotic therapy
chronic coronary syndrome
rivaroxaban
ticagrelor
clopidogrel
prasugrel
Online Erişim:https://journals.viamedica.pl/cardiology_journal/article/view/104821
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller